FDA Peptide Tracker

GHRP-2 / GHRP-6: live FDA regulatory status

GH-releasing peptides · RFK-14

The two signals

Plain-English verdict: red.

Regulatory status: Expected to stay restricted.

These two never collapse into one. Removal from a list is not the same as legal-to-compound, and neither is the same as available.

Availability at Peptós.LIFE

Education only

What happens next

Status review (projected) — 2026–2027

Regulatory timeline

GHRP-2 / GHRP-6: common questions

Is GHRP-2 / GHRP-6 legal in 2026?
No. GHRP-2 / GHRP-6 is expected to remain restricted. We do not expect a near-term pathway that would make it legitimately compoundable.
Can I get GHRP-2 / GHRP-6 right now?
No. GHRP-2 / GHRP-6 is education-only at Peptós.LIFE and we will not put it on a waitlist we do not expect to be able to fill.
Why is GHRP-2 / GHRP-6 listed if it is not available?
Because people are searching for it and deserve a straight answer with a date on it. Tracking a molecule is not the same as offering it, and we would rather be the page that says no than let a research-chemical seller answer the question.
What happens next for GHRP-2 / GHRP-6?
Status review (projected), 2026–2027. We will update this page the day the FDA does anything that changes it.

PCAC is advisory: its Jul 2026 recommendation leads to rulemaking, not instant availability. A favorable advisory vote is a recommendation, not FDA approval or authorization to compound. Realistic earliest legitimate access is late 2026 into 2027. Reclassification is not the same as FDA approval. Compounded medications are not evaluated or approved by the FDA for safety, efficacy, or quality, where that applies, we say so, plainly.

Primary source: FDA source record

See the full status board.

Embed this card on your site · free, CC BY 4.0, no key.

Last updated July 26, 2026 · Peptós.LIFE · Not medical advice.